Apicore is an API manufacturer based in India. It holds 35 active US drug master files and one valid CEP. Its GMP standing is certified by US FDA, CDSCO (India) and EDQM. Its most recent recorded inspection, by US FDA, closed on 12 December 2025 as VAI. Customs aggregates show $15.4M of exports covering 148 molecules to 18 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Anakapalli, India | 3012575874 |
| Hyderabad, India | 3007136165 |
| Vadodara, India | 3006767695 |
| tal padravadodara, India | Not on file |
| Somerset, United States | Not on file |
| East Windsor Township, United States | 3004864046 |
| Molecule | Regulators | Docs |
|---|---|---|
| Plerixafor | SFDA (Saudi Arabia), US FDA | 3 |
| Belzutifan | US FDA | 2 |
| Busulfan | EDQM, US FDA | 2 |
| Cevimeline | US FDA | 2 |
| Cyclophosphamide | US FDA | 2 |
| Ferric Carboxymaltose | US FDA | 2 |
| Ferumoxytol | US FDA | 2 |
| Flibanserin | US FDA | 2 |
| Fluorescein | US FDA | 2 |
| Ganirelix | US FDA | 2 |
| Lurbinectedin | US FDA | 2 |
| Metyrosine | US FDA | 2 |
| Miglustat | SFDA (Saudi Arabia), US FDA | 2 |
| Selegiline | US FDA | 2 |
| Semaglutide | US FDA | 2 |
| Trabectedin | US FDA | 2 |
| Alcaftadine | US FDA | 1 |
| Bexarotene | US FDA | 1 |
| Bortezomib | US FDA | 1 |
| Cetrorelix | US FDA | 1 |
| Degarelix | US FDA | 1 |
| Dimetindene | SFDA (Saudi Arabia) | 1 |
| Indocyanine Green | US FDA | 1 |
| Maralixibat | US FDA | 1 |
| Oseltamivir | US FDA | 1 |
| Penicillamine | US FDA | 1 |
| Pentosan Polysulfate Sodium | US FDA | 1 |
| Perphenazine | US FDA | 1 |
| Phentolamine | US FDA | 1 |
| Raltegravir | US FDA | 1 |
| Safinamide | US FDA | 1 |
| Sugammadex | SFDA (Saudi Arabia) | 1 |
| Tetraferric Tricitrate Decahydrate | US FDA | 1 |
| Tirzepatide | US FDA | 1 |
| Vosoritide | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 2 |
| CDSCO (India) | None | 2 |
| EDQM | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $875K | 4 |
| 2025 | Not reported | $15.4M | 18 |
| 2024 | Not reported | $9.3M | 11 |
| 2023 | Not reported | $7.1M | 15 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Apicore comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.